We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > TD213

News List

TrippBio Reports Positive Results from Investigator-Initiated Clinical Trial of TD213 for the Treatment of Mild to Moderate COVID-19 Infections prnewswire
November 17, 2020
TrippBio is dedicated to developing groundbreaking treatments for viral infections, initially targeting COVID-19. TrippBio is developing a patent-pending repurposed FDA-approved drug called TD213.
TrippBio Completes Trial Enrollment to Evaluate Efficacy of TD213 for COVID-19 americanpharmaceuticalreview
October 29, 2020
TrippBio is developing a patent-pending repurposed FDA-approved drug, TD213. TD213 works by blocking the SARS-CoV-2 virus' replication and the associated acute inflammatory response to the infection.
TrippBio Announces the Completion of Enrollment in a Proof of Concept Clinical Trial Evaluating the Efficacy of TD213 in Treating Patients with Confirmed COVID-19 Infections prnewswire
October 23, 2020
TrippBio is a biotechnology company dedicated to developing groundbreaking treatments for viral infections initially targeting the global pandemic caused by COVID-19.